Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]

Dahl R, Jadayel D, Alagappan VKT, Chen H, Banerji D. *Int J Chron Obstruct Pulmon Dis*. 2013;8:501–508.

On page 501, note that in the Results section of the Abstract, the sentence “Trough FEV_1 at week 4 for QVA149 and IND+GLY was $1.46 \text{ L} \pm 0.02$ and $1.46 \text{ L} \pm 0.18$, respectively.” should read “Trough FEV_1 at week 4 for QVA149 and IND+GLY was $1.5 \text{ L} \pm 0.02$.”

On page 505, note that the sentence “The least squares mean $\pm$ standard error (LSM $\pm$ SE) trough FEV_1 at week 4 for QVA149 and for the free-dose combination of IND+GLY was $1.5 \text{ L} \pm 0.02$ and $1.5 \text{ L} \pm 0.18$, respectively (Figure 3).” should read “The least squares mean $\pm$ standard error (LSM $\pm$ SE) trough FEV_1 at week 4 for QVA149 and for the free-dose combination of IND+GLY was $1.5 \text{ L} \pm 0.02$ (Figure 3).”

On page 505, note that the confidence interval for Figure 3 was incorrect, and the confidence intervals and y-axis for

Figure 4 were also incorrect. The full and correct figures are given here.

Figure 4 FEV_1 AUC_{0-4 hours} at day 1 and week 4.

Abbreviations: FEV_1 , forced expiratory volume in 1 second; AUC, area under curve; IND+GLY, indacaterol and glycopyrronium; CI, confidence interval.

Figure 3 Trough FEV_1 (L) at week 4.

Abbreviations: IND+GLY, indacaterol and glycopyrronium; FEV_1 , forced expiratory volume in 1 second; CI, confidence interval.